Metropolis Healthcare on Thursday said its net profit declined 15 per cent to Rs 29 crore for the first quarter ended June 30, 2023. The diagnostics firm had reported a net profit of Rs 34 crore in the April-June quarter of the last fiscal. Revenue from operations declined to Rs 277 crore from Rs 280 crore in the year-ago period, Metropolis Healthcare said in a statement. Metropolis Healthcare Promoter and Managing Director Ameera Shah said the company remains optimistic about scaling up revenue in the upcoming quarters, indicating positive operating leverage play. "Going forward, company focuses on network expansion, increasing doctor connects, growing specialised & wellness segments and upgrading IT infrastructure for enhancing the consumer experience," she added.
In 2021-22, Covid19 business was almost 20-22% of the revenue for most diagnostic companies. The non-Covid19 business is not going to grow by 22% to make it equal
Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.
Competitive pressures, valuations cap gains from current levels
The Income-tax department on Wednesday conducted searches at the premises of Mumbai-based Metropolis Healthcare that runs medical diagnostic centres as part of a tax evasion investigation, official sources said. The locations of the company in Mumbai are being covered, they said. A response from the company is awaited. The company is a prominent player in the medical tests and diagnostics business domain. It had last week reported a consolidated profit after tax of Rs 40.5 crore for the second quarter that ended September 30.
According to the technical analyst from Anand Rathi, Metropolis Healthcare can rally to Rs 1,800, while Thyrocare Technologies can rise up to Rs 740.
According to the technical analyst from Anand Rathi, Raymond can rally to Rs 1,100, while Metropolis Healthcare can surge to Rs 1,620.
In the past one year, these stocks have slipped between 48 per cent and 51 per cent, as compared to 3 per cent gain in the Sensex
In a Q&A, the promoter and MD of the company talks about how the dynamics are changing in the diagnostics sector post Covid, and outlines her strategy for Metropolis 3.0
"The company, its promoters and management team are committed to operating Metropolis Healthcare Ltd with the highest standards of medical science, stakeholder trust and customer engagement," the comp
Metropolis Healthcare is continuously exploring various strategic options and investment
The promoters of Metropolis Healthcare on Monday after market hours clarified that they have no intention to exit the business.
Stocks to watch today: Bajaj Finance has raised fixed deposit rates by up to 20 basis points; Zydus Lifesciences will open its share buyback offer on June 23 and close on July 6.
Promoters are focused on strengthening the Metropolis brand, although it continuously keeps exploring various strategic options/investment opportunities
The RBI today raised the repo rate to 4.9 per cent, up from 4.4 per cent. The Central Bank also raised consumer price (CPI) or retail inflation forecast for FY23 to 6.7 per cent from 5.7 per cent.
Adani and Apollo's deal with Metropolis could be at least worth $1 billion or Rs 7,765 crore, given the market captalisation of the diagnostic chain
CLOSING BELL: The broader markets, meanwhile, bled more with the BSE SmallCap index sliding nearly 3 per cent, and the BSE MidCap index falling close to 2 per cent
Stocks to Watch Today: Sugar and FMCG stocks likely to be in focus as govt limits sugar exports and exempts customs duty on agri cess. Apollo Hospitals, Bata, Coal India and Nalco to report results.
Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
The company is planning to add around 40 more Hitech centres during the current financial year